Spanish multicenter tafluprost tolerability study

British Journal of Ophthalmology

Volumn 96, Issue 6, 2012, Pages 826-831

  Milla, Elena ^a,b   Stirbu, Oana ^a   Rey, Amanda ^b   Duch, Susana ^a   Buchacra, Oscar ^a   Robles, Amelia ^c   Navarro, Catalina ^d   Gil, Rafael ^e   Cordero, Jose Maria ^f  

^a Glaucoma Unit   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL NUESTRA SEÑORA DE SONSOLES   (Spain)

^d Institut Clinica Corachan   (Spain)

^e HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^f Althaia   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; DRUG PRESERVATIVE; PROSTAGLANDIN DERIVATIVE; SAFLUTAN; TAFLUPROST; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLEPHARITIS; CLINICAL FEATURE; CONJUNCTIVAL HYPEREMIA; DISEASE SEVERITY; DRUG TOLERABILITY; DRY EYE; EYE BURNING; EYE DISEASE; EYE IRRITATION; EYE STINGING; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; KERATITIS; LACRIMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OCULAR PRURITUS; OCULAR SURFACE SYMPTOM; OPEN STUDY; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHIRMER TEST; SYMPTOM; TEAR BREAK UP TIME; TEAR MENISCUS; VISUAL SYSTEM PARAMETERS;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CONJUNCTIVA; CORNEA; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PRESERVATIVES, PHARMACEUTICAL; PROSPECTIVE STUDIES; PROSTAGLANDINS F; SPAIN; TONOMETRY, OCULAR;

EID: 84861331718     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2011-301015     Document Type: Article

References (20)

1. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study. Baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-20. (Pubitemid 34620349)
2. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. Am J Ophthalmol 2002;134:499-512.
3. Collaborative Normal Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal tension glaucoma. Am J Ophthalmol 1998;126:498-505.
4. European Glaucoma Society. Treatment principles and options. In: Heijl A, Traverso C, eds. Terminology and Guidelines for Glaucoma. 3rd edn. Savona: Editrice Dogma, 2008:136-9.
5. Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Ophthalmology 2009;116:191-9.
6. Traverso CE, Walt JG, Stern LS, et al. Pharmacotherapy compliance in patients with ocular hypertension or primary open-angle glaucoma. J Ocul Pharmacol Ther 2009;25:77-82.
7. Quek DT, Ong GT, Perera SA, et al. Persistence of patients receiving topical glaucoma monotherapy in an Asian population. Arch Ophthalmol 2011;129:643-8.
8. Beckers HJ, Schouten JS, Webers CA, et al. Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction. Graefes Arch Clin Exp Ophthalmol 2008;246:1485-90.
9. Silva LR, de Paula JS, Rocha EM, et al. Factors related to glaucoma treatment compliance: patients' opinions from a University Hospital. Arq Bras Oftalmol 2010;73:116-19.
10. Bresson-Dumont H. Ocular intolerance to antiglaucoma medications is underestimated. Bull Soc Belge Ophtalmol 2010;315:47-53.
11. Sutton A, Gouws P, Ropo A. Tafluprost, a new potent prostanoid receptor agonist: a dose-response study on pharmacodynamics and tolerability in healthy volunteers. Int J Clin Pharmacol Ther 2008;46:400-6.
12. Sutton A, Gilvarry A, Ropo A. A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males. J Ocul Pharmacol Ther 2007;23:359-65. (Pubitemid 350195060)
13. Alm A, Grierson I, Shields B. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol 2008;53:S93-105.
14. Ahiara M. Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Clin Ophthalmol 2010;4:163-70.
15. Pozarowska D. Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension. Clin Ophthalmol 2010;21:1229-36.
16. Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol 1996;7:80-6. (Pubitemid 26268834)
17. Kahook MY, Noecker R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv Ther 2008;25:743-51.
18. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002;86:418-23. (Pubitemid 34293291)
19. Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol 2010;88:329-36.
20. Hommer A, Kimmich F. Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost. Clin Ophthalmol 2011;5:623-31.